INTRODUCTION AND OBJECTIVES:
Clear cell papillary renal cell carcinoma (CCP-RCC) represents the fourth most common renal cell carcinoma (RCC) after conventional clear cell, papillary and chromophobe RCC. Although patients with CCP-RCC behave in an indolent fashion in reported cases, long-term clinical outcomes remain unclear. Also, only limited molecular information is available in CCP-RCC, which has primarily been focused on VHL alterations. In this study we aimed to better understand the mutational landscape of CCP-RCC and provide extended follow up information.
METHODS: A retrospective search of our institutional database from 1997-2017 yielded 64 cases of CCP-RCC treated by surgical resection. Follow up was obtained for all patients. 17 cases that showed classic morphology and immunoprofile of CCP-RCC were selected for molecular testing. We used the Oncomine Comprehensive Assay v3 (ThermoFisher) that covers 161 cancer-related genes including 51 fusion drivers, 91 copy number variants, 48 full-length genes and 87 hotspot mutations. HDx positive controls were used and 90% of expected variants were detected. Average read depth per sample was 1418x.
RESULTS: For the cohort of 64 CCP-RCC, the mean patient age was 60 years (range 34-82) with a 1.6:1 male:female ratio. CCP-RCC was identified in the context of end-stage renal disease in 29.7% of the cases. No recurrence or metastasis was detected in any case after a mean follow up of 57 months (range 1-240 months). In the subset of 17 CCP-RCC that underwent sequencing, seven cases (41.1%) showed no mutations in the cancer-related genes tested, eight (47.1%) cases had a single mutation, and only two (11.8%) cases had 2 mutations (Table 1) . No fusion drivers were detected.
CONCLUSIONS: All 64 patients with CCP-RCC had indolent behavior after a maximum follow up of twenty years. Targeted sequencing of 17 cases showed recurrent somatic mutations in ARID1A, NOTCH3, KIT and TSC1 in subsets of tumors. Nearly half of the cases had no detectable mutation at all. This study is the largest and most comprehensive molecular characterization of CCP-RCC to date and reports the longest available follow up. Our findings support the notion that CCP-RCC harbors a unique mutational landscape and follows an indolent clinical course. 
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INTRODUCTION AND OBJECTIVES:
MiT family translocation renal cell carcinoma (RCC) is very rare variant which has translocation of Xp11.2/TFE3 gene or t(6;11)/TFEB gene. Xp11.2 translocation RCC is predominantly reported in younger age and has aggressive features. However, its pathophysiology or genetic characteristics are rarely understood. The aim of the study is to describe the comprehensive genetic characteristics of TFE3-positive RCC diagnosed by immunohistochemistry.
METHODS: We identified patients who were clinically diagnosed as Xp11.2 translocation RCC by immunostaining positive of TFE3 from two tertiary referral hospitals. Among them, a total of 19 patients whose fresh frozen tissue and normal DNA were achieved were included in the analysis. Whole exome sequencing (WES) was performed to evaluate somatic mutations and copy-number variation (CNV). We also performed RNAseq on the TFE3-positive RCC, 7 clear cell RCC, and 4 normal kidney tissue for comparison. Fusion partners were identified and clustering analysis was done by RNAseq.
RESULTS: Mutational landscape of TFE3-positive RCC is unique by low somatic mutation rate and very rare COSMIC variants. High prevalence of CNV with loss of 3p, 6q, 9, gain of 5, 7, and 12 were most frequent. We identified NONO, RBM10, SFPQ, ASPSCR1 and PRCC as fusion partner as previously described. We could not find TFE3 fusion in 4 out of 19 patients by RNAseq, and they were older and had more mutations than the others. They were also genetically clustered with clear cell RCC. Oxidative reducatase pathway was upregulated and immune response and cell adhesion were downregulated by gene ontology results from heatmap clusters. These may promote metastasis, resistant to immunity and cell survival in poorer condition which could be potential mechanism of Xp11.2 translocation RCC aggressiveness.
CONCLUSIONS: TFE3-positive RCC showed distinctive mutation pattern with low somatic mutation and rare common driver gene. A quarter of clinically diagnosed Xp11.2 translocation RCC (4/19) did not have real gene fusion even in TFE3 overexpression. They were older and had more somatic mutations than the others. Furthermore, they were clustered with clear cell RCC. . 199, No. 4S, Supplement, Sunday, May 20, 2018 
